Bridgefront Capital’s Tyra Biosciences TYRA Stock Holding History

Bridgefront Capital’s Portfolio TYRA Stock Details TYRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,911	Closed	-$303K	–	759
2026 Q1	$303K	Buy	+7,911	New	+$256K	0.08%	390

Other funds holding TYRA

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

APMC

Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Bridgefront Capital's TYRA Position: Q2 2026 in Review

Bridgefront Capital sold out of Tyra Biosciences (TYRA) in Q2 2026, closing a stake of 7,911 shares — an estimated $303K sold.

Bridgefront Capital first reported a position in TYRA in Q1 2026 and held it in 1 quarter. The position peaked at $303K in Q1 2026. 168 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

Bridgefront Capital reported no remaining Tyra Biosciences position as of Q2 2026 after selling out during the quarter.
Bridgefront Capital sold 7,911 Tyra Biosciences shares in Q2 2026, an estimated $303K.
Bridgefront Capital first reported a position in Tyra Biosciences in Q1 2026 and held it in 1 quarter.
Bridgefront Capital's Tyra Biosciences position peaked at $303K in Q1 2026.
168 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.